# A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)

> **NCT02013219** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 52 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Alectinib
- **DRUG:** Atezolizumab
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT02013219
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-03
- **Primary completion:** 2020-02-05
- **Final completion:** 2020-02-05
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2020-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02013219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02013219, "A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02013219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*